A prospective, open-label, multicenter, phase IV clinical study to evaluate the long term persistence of immunological response after primary vaccination with Typhoid Vi Conjugate Vaccine and response to booster dose vaccination with Typhoid Vi Conjugate Vaccine of M/s Cadila Healthcare Limited in healthy subjects - None
Latest Information Update: 31 Jan 2020
At a glance
- Drugs Typhoid vaccine Vi conjugate (Primary)
- Indications Typhoid
- Focus Pharmacodynamics
- Sponsors Zydus Lifesciences
Most Recent Events
- 31 Jan 2020 New trial record